Valuation: TG Therapeutics, Inc.

Market Cap 7.17B 6.14B 5.75B 5.26B 9.87B 686B 10.01B 67.91B 26.48B 345B 26.93B 26.34B 1,140B P/E 2026 *
53.4x
P/E 2027 * 17.7x
Enterprise Value 7.34B 6.29B 5.88B 5.39B 10.11B 702B 10.24B 69.51B 27.11B 353B 27.56B 26.96B 1,167B EV / Sales 2026 *
7.65x
EV / Sales 2027 * 5.18x
Free-Float
88.56%
Yield 2026 *
-
Yield 2027 * -
1 day+9.48%
1 week+13.93%
Current month+6.73%
1 month+2.93%
3 months+41.51%
6 months+81.65%
Current year+86.28%
1 week 48.5
Extreme 48.5
56.87
1 month 45.36
Extreme 45.365
57.58
Current year 26.76
Extreme 26.76
59.3
1 year 26.76
Extreme 26.76
59.3
3 years 6.46
Extreme 6.46
59.3
5 years 3.48
Extreme 3.48
59.3
10 years 3.32
Extreme 3.32
59.3
Manager TitleAgeSince
Chief Executive Officer 60 29/12/2011
Director of Finance/CFO 44 29/12/2011
Investor Relations Contact - 01/12/2011
Director TitleAgeSince
Chairman 60 29/12/2011
Director/Board Member 79 01/03/2012
Director/Board Member 62 09/11/2012
Date Insider Type Main position Quantity % Market Cap.
7/8/26 Don

Director

-950 0.0006%
28/1/26 Don

Director

43,197 0.0272%
8/1/26 Free

Chief Executive Officer

622,000 0.3918%
Change 5-day change 1-year change 3-year change Capi.($)
+9.62%+13.93%+93.01%+435.49% 7.17B
+1.66%+6.96%+77.83%+129.49% 1,109B
+1.64%+4.13%+51.52%+62.00% 644B
+1.48%+6.40%+26.70%+76.76% 463B
+1.02%+5.77%+43.09%+47.70% 371B
+0.85%+4.07%+23.88%+41.58% 301B
+1.26%+6.81%+1.59%+14.67% 256B
+1.46%+5.47%+48.06%+67.97% 234B
+1.59%+2.09%-15.52%-52.29% 205B
+2.17%+5.95%+26.22%+93.03% 178B
Average +2.26%+3.25%+37.64%+91.64% 376.82B
Weighted average by Cap. +1.50%+3.26%+44.82%+73.77%

Financials

2026 *2027 *
Net sales 960M 822M 770M 704M 1.32B 91.87B 1.34B 9.09B 3.55B 46.15B 3.61B 3.53B 153B 1.32B 1.13B 1.06B 967M 1.81B 126B 1.84B 12.48B 4.87B 63.35B 4.95B 4.84B 210B
Net income 157M 135M 126M 115M 217M 15.06B 220M 1.49B 581M 7.57B 591M 578M 25.02B 450M 386M 361M 330M 620M 43.07B 628M 4.26B 1.66B 21.64B 1.69B 1.65B 71.56B
Net Debt 169M 145M 135M 124M 233M 16.17B 236M 1.6B 624M 8.12B 635M 621M 26.87B -348M -298M -279M -255M -479M -33.3B -485M -3.3B -1.29B -16.73B -1.31B -1.28B -55.32B
Logo TG Therapeutics, Inc.
TG Therapeutics, Inc. is a fully integrated, commercial stage biotechnology company focused on the acquisition, development and commercialization of novel treatments for B-cell diseases. Its products include Ublituximab IV (anti-CD20 mAb), Ublituximab IV Simplified Dosing Schedule, Ublituximab Subcutaneous (anti-CD20 mAb), and Azer-cel. It is engaged in late-stage clinical development of BRIUMVI. BRIUMVI is an anti-CD20 monoclonal antibody that can be administered to adults with relapsing forms of multiple sclerosis (RMS) in a one-hour infusion every 24 weeks, following the starting dose. It is used for treatment of adults with clinically isolated syndrome, relapsing-remitting disease, and active secondary progressive disease. The Company is also engaged in ULTIMATE I & II Trials Evaluating Single Agent Ublituximab in RMS. Its ENHANCE Phase 3b Trial is an ongoing, multi-center, open-label study designed to evaluate alternative dosing regimens for BRIUMVI in patients with RMS.
Employees
399
Date Price Change Volume
22/08/26 USD 55.64 +10.05% 3,439,876
20/08/26 USD 50.56 -2.19% 2,435,627
19/08/26 USD 51.69 +2.85% 1,289,534
18/08/26 USD 50.26 +1.99% 1,195,008
17/08/26 USD 49.28 +1.11% 1,062,887
Trader
Investor
Global
Quality
ESG MSCI
CCC
Sell
Consensus
Buy
Mean consensus
BUY
Number of Analysts
8
Last Close Price
50.56USD
Average target price
69.71USD
Spread / Average Target
+37.88%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. TGTX Stock